{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 447995846
| IUPAC_name = 4-hydroxy-''N'',1-dimethyl-2-oxo-''N''-<br>phenyl-1,2-dihydroquinoline-3-carboxamide
| image = Roquinimex.svg

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life = 26-42 hours
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 84088-42-6
| ATC_prefix = L03
| ATC_suffix = AX02
| PubChem = 55197
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 372T2944C0
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 10619239

<!--Chemical data-->
| C=18 | H=16 | N=2 | O=3 
| molecular_weight = 308.331 g/mol
| smiles            = CN1C2=CC=CC=C2C(=C(C1=O)C(=O)N(C)C3=CC=CC=C3)O
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C18H16N2O3/c1-19(12-8-4-3-5-9-12)17(22)15-16(21)13-10-6-7-11-14(13)20(2)18(15)23/h3-11,21H,1-2H3
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = SGOOQMRIPALTEL-UHFFFAOYSA-N

}}
'''Roquinimex''' (Linomide) is a [[quinoline]] derivative [[immunostimulant]] which increases [[Natural killer cell|NK cell]] activity and [[macrophage]] [[cytotoxicity]]. It also inhibits [[angiogenesis]] and reduces the secretion of [[Tumor necrosis factor-alpha|TNF alpha]].

Roquinimex has been investigated as a treatment for some cancers (including as adjuvant therapy after [[Hematopoietic stem cell transplantation|bone marrow transplantation]] in acute [[leukemia]]) and autoimmune diseases, such as [[multiple sclerosis]] and recent-onset [[Diabetes mellitus type 1|type I diabetes]]. Several trials have been terminated due to serious cardiovascular toxicity.

==Synthesis==
[[File:Roquinimex synthesis.svg|thumb|center|700px|Roquinimex synthesis:<ref>E. Eriksoo et al., {{Cite patent|EP|59698}}; eidem, {{US patent|4738971}} (1982, 1988 both to AB Leo).</ref>]]
Ethyl 2-(methylamino)benzoate is condensed with [[ethyl malonate]]. Amine-ester ineterchange of that compound with [[N-methylaniline]] results in formation of the amide roquinimex.

{{Immunostimulants}}

==References==
{{Reflist}}

[[Category:Immunostimulants]]
[[Category:2-Quinolones]]
[[Category:Quinolinols]]
[[Category:Carboxamides]]
[[Category:Anilides]]


{{antineoplastic-drug-stub}}